Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2020 10:51

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Read more
16 Jan 2020 18:15

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Read more
14 Jan 2020 16:10

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Read more
6 Jan 2020 17:29

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 11:49

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 10:55

Open Orphan inks three-year contract with mystery European firm

(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.

Read more
31 Dec 2019 09:46

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Read more
31 Dec 2019 06:31

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Dec 2019 12:54

Open Orphan signs deal with US biopharmaceutical firm SFA

(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.

Read more
18 Dec 2019 12:29

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Read more
9 Dec 2019 14:36

Open Orphan agrees acquisition of hVIVO at 34% premium

(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.

Read more
9 Dec 2019 11:23

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Read more
25 Nov 2019 14:57

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Read more
18 Nov 2019 10:35

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Read more
18 Nov 2019 09:58

Open Orphan signs pharmacology trial contract with Carna

(Sharecast News) - Rare and orphan drug consulting services provider Open Orphan announced the signing of a contract with Carna Bioscience for a first-in-human clinical pharmacology trial, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.